cagrilintide fda (10mg vials) 1 CagriSema 2.4 mg /

Cagrilintide monotherapy remains investigational, and the CagriSema combination although it has been submitted for regulatory review remained unapproved as of this writing

Cagrilintide has no boxed warning because it has no approved label which reflects its investigational status, not proven long-term safety

Enebo LB, Berthelsen KK, Kankam M, et al

doi:10.1016/S0140-6736(21)00845-X

Our reference on the cagrilintide-and-semaglutide combination in obesity research keeps the two apart

Cagrilintide as a stand-alone drug has been studied through Phase 2, [1] but most of the headline cagrilintide numbers people cite actually come from CagriSema the fixed-dose combination of cagrilintide 2.4 mg with semaglutide 2.4 mg which advanced into the Phase 3 REDEFINE program